At the University of Bristol, researchers using computational modeling have found that certain vitamins and existing drugs may bind to a specific pocket in the COVID-19 spike protein, holding it in a closed, less infectious form. The discovery suggests that compounds like vitamins D, K, and A — long understood as immune supporters — may also act as direct antivirals, while high cholesterol appears to work in the opposite direction, favoring the virus. In a moment when the world searches urgently for tools against a novel pathogen, science is finding that some answers may already reside in fami
Bristol study identifies vitamins D, K, A as potential COVID-19 treatments via spike protein binding
Deficiency in any one of them may make it easier for the virus to infect.
Mark
So the researchers found that certain vitamins can bind to the spike protein. But how confident are they that this actually matters in a real infection?
Mimi
That's the crucial next step. Right now they've shown it computationally—the molecules fit into this pocket and the math suggests they stabilize the closed form. But they haven't yet tested whether that actually slows down viral replication in living cells. That's what comes next.
Mark
Why does it matter that cholesterol seems to do the opposite—to open the spike up?
Mimi
Because it explains something doctors were already seeing: people with high cholesterol were getting sicker from COVID. The simulations suggest the virus might actually be pulling cholesterol out of your bloodstream to help itself infect cells. It's not just a risk factor—it might be part of the virus's strategy.
Mark
The study mentions obesity as a risk factor and vitamin D accumulating in fat tissue. Is that saying obese people can't use vitamin D as well?
Mimi
Essentially, yes. Vitamin D is fat-soluble, so it gets stored in fatty tissue rather than staying in circulation where your immune system can use it. An obese person might consume enough vitamin D, but less of it is available to fight infection. That's one reason the researchers think vitamin deficiencies matter so much in this pandemic.
Mark
If these vitamins work, why haven't we heard more about it in the news?
Mimi
Because this is computational modeling, not clinical proof. They're showing the mechanism—how the molecules fit and what should happen. But until they test it in cells and eventually in people, it's still a hypothesis. The real value is that it gives researchers a target and a reason to test these compounds seriously.
Mark
Does this mean people should start taking vitamin D supplements to prevent COVID?
Mimi
The study doesn't say that. It identifies a potential mechanism, but that's different from proving a treatment works in humans. What it does suggest is that vitamin deficiencies might make infection easier, which is worth investigating further.
Le Pouls
- A newly identified 'druggable pocket' in the COVID-19 spike protein has become the focal point of a race to find faster antiviral solutions without waiting years for traditional drug development.
- The discovery that dexamethasone — already saving lives — binds to this same site reframes how existing treatments may be working, adding urgency to the question of what else might do the same.
- Cholesterol emerges as a troubling counterforce: high levels appear to destabilize the spike's closed form, potentially explaining why obesity and cardiovascular risk factors correlate so strongly with severe disease.
- Vitamins D, K, and A are now candidates for direct antiviral action, not just immune support — a shift that recontextualizes widespread deficiencies as possible vulnerabilities in the population's defense.
- Researchers are moving from simulation to laboratory validation, testing dietary supplements against live viral replication in cells, with the hope of accelerating a new class of targeted antivirals.
At the University of Bristol, researchers using computational modeling have found that certain vitamins and existing drugs may bind to a specific pocket in the COVID-19 spike protein, holding it in a closed, less infectious form. The discovery suggests that compounds like vitamins D, K, and A — long understood as immune supporters — may also act as direct antivirals, while high cholesterol appears to work in the opposite direction, favoring the virus. In a moment when the world searches urgently for tools against a novel pathogen, science is finding that some answers may already reside in familiar molecules, waiting to be understood anew.
Researchers at the University of Bristol have used computational simulations to identify a specific site on the COVID-19 spike protein — a pocket that, when occupied by certain molecules, locks the protein in a closed, less infectious form. The spike must open to bind with ACE2 receptors on human cells; keeping it shut reduces the virus's ability to enter. The discovery builds on an earlier finding that linoleic acid, a common dietary fatty acid, stabilizes this closed conformation. The Bristol team then searched libraries of approved drugs and vitamins to find other compounds that might work the same way.
The simulations produced striking results. Dexamethasone, already established as an effective COVID-19 treatment, also binds to this pocket — suggesting its benefits may extend beyond immune modulation to a direct effect on the spike protein itself. Fat-soluble vitamins D, K, and A emerged as additional candidates binding the same site. The research also shed light on why vitamin D deficiency may worsen outcomes: being fat-soluble, it accumulates in fatty tissue and may be less bioavailable in obese individuals, precisely those at greatest risk.
Cholesterol told a darker story. The spike protein binds cholesterol, and high levels appear to favor the open, more infectious conformation — aligning with clinical data showing that statins reduce severe disease risk. The virus may even draw cholesterol from the bloodstream to facilitate cell entry, which could explain the drop in circulating cholesterol observed after infection.
Professor Adrian Mulholland and Dr. Deborah Shoemark, who led the spike protein analysis, emphasized that the next step is experimental: testing these compounds in cell cultures to measure their effect on viral replication. The work, conducted across multiple Bristol departments using high-performance computing including the UK's ARCHER supercomputer, was published in Angewandte Chemie. If laboratory results confirm the simulations, the findings could offer a molecular shortcut — a defined target that bypasses years of conventional drug discovery and accelerates the development of new antivirals.
Researchers at the University of Bristol have identified a potential mechanism by which certain vitamins and existing drugs might help the body fight COVID-19. Using computational simulations, they discovered that vitamins D, K, and A—along with linoleic acid and several approved medications—can bind to a specific pocket within the coronavirus spike protein, effectively locking it into a closed, less infectious form. The findings, published in Angewandte Chemie, the journal of the German Chemical Society, suggest a direct antiviral pathway that goes beyond these compounds' conventional role in supporting immune function.
The research began with an earlier discovery: linoleic acid, a fatty acid found in foods, binds to a particular site on the spike protein and stabilizes its closed conformation. This matters because the spike protein must open to interact with ACE2, a receptor on human cells, in order for the virus to infect them. By keeping the spike locked shut, linoleic acid reduces the virus's ability to enter cells. The Bristol team then used computational methods to search through libraries of approved drugs and vitamins to identify other compounds that might work the same way. Rather than waiting years for new drugs to be designed, tested, and approved—the traditional path for antiviral development—they looked for existing molecules that could target this newly discovered "druggable pocket."
The simulations revealed that dexamethasone, already known to be an effective COVID-19 treatment, also binds to this site. This finding suggests that at least part of dexamethasone's benefit may come from directly stabilizing the spike protein in its closed form, in addition to its known effects on the immune system. The team then expanded the search, identifying fat-soluble vitamins D, K, and A as candidates that bind to the same location. Several other compounds with known antiviral activity in laboratory tests also emerged as potential binders, suggesting this mechanism may explain how some existing treatments work against the virus.
Dr. Deborah Shoemark, the biomolecular modeler who led the spike protein analysis, emphasized the practical implications. Vitamin D, being fat-soluble, tends to accumulate in fatty tissue rather than circulate freely in the bloodstream. This means obese individuals—who face elevated risk from severe COVID-19—may have lower available levels of the vitamin despite adequate intake. Countries where vitamin D deficiency is more prevalent have also experienced worse pandemic outcomes. The research suggests that deficiencies in any of these protective compounds—whether vitamins or fatty acids—could make infection easier for the virus.
The study also examined cholesterol, which the spike protein is known to bind. High cholesterol is a documented risk factor for severe COVID-19, and the simulations indicate why: cholesterol appears to destabilize the spike's closed form, favoring the open, more infectious conformation. This finding aligns with clinical observations that cholesterol-lowering statins reduce the risk of severe disease and shorten recovery time in milder cases. The virus may even sequester cholesterol from the bloodstream to achieve the local concentrations it needs to facilitate cell entry, which could explain the drop in circulating cholesterol observed after infection.
Professor Adrian Mulholland, from Bristol's School of Chemistry, noted that the simulations demonstrate how molecules binding at the linoleic acid site can lock the spike closed, and that drugs and vitamins already known to be active against the virus may operate through this same mechanism. The next phase of research will move from computational prediction to experimental validation: testing the effects of dietary supplements and measuring viral replication in cell cultures. The work involved researchers across multiple Bristol departments—Chemistry, Biochemistry, Cellular and Molecular Medicine, and the Max Planck Bristol Centre for Minimal Biology—using high-performance computers and the UK's ARCHER supercomputer, along with Oracle cloud infrastructure. If the laboratory tests confirm these predictions, the findings could accelerate the development of new antivirals by providing a clear molecular target and a shortcut past years of traditional drug discovery.
Citations marquantes
Our findings help explain how some vitamins may play a more direct role in combatting COVID than their conventional support of the human immune system.— Dr. Deborah Shoemark, University of Bristol
Targeting this site may be a route to new anti-viral drugs.— Professor Adrian Mulholland, University of Bristol
Envie de l'histoire complète ?
Lire l'original sur Devdiscourse ↗
Health & Medicine